If you require further searching capabilities for announcements please email: data@nzx.com
Cannasouth Limited's (NZX:CBD, Cannasouth) wholly owned subsidiary Cannasouth Bioscience Limited has received approval for an additional activity under its commercial Medicinal Cannabis Licence by the Medicinal Cannabis Agency (Agency) for its facilities based in Hamilton. The new supply activity is additional to existing cultivation and possession for manufacture activities on the license. This licence means Cannasouth is ready to distribute its imported own brand products, once registered with the Agency. Cannasouth submitted its product assessment applications for its first three products to the Agency in November 2020. -ENDS- For further information visit www.cannasouth.co.nz or contact: Mark Lucas CEO, Cannasouth Limited Email: mark.lucas@cannasouth.co.nz Mobile: 021 484 649 Colin Foster CFO, Cannasouth Limited Email: colin.foster@cannasouth.co.nz Mobile: 027 577 1498 End CA:00370891 For:CBD Type:MKTUPDTE Time:2021-04-19 15:04:39